Giuseppe Privitera

1.0k total citations · 1 hit paper
31 papers, 656 citations indexed

About

Giuseppe Privitera is a scholar working on Genetics, Immunology and Surgery. According to data from OpenAlex, Giuseppe Privitera has authored 31 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Genetics, 13 papers in Immunology and 9 papers in Surgery. Recurrent topics in Giuseppe Privitera's work include Inflammatory Bowel Disease (15 papers), Microscopic Colitis (7 papers) and Biosimilars and Bioanalytical Methods (7 papers). Giuseppe Privitera is often cited by papers focused on Inflammatory Bowel Disease (15 papers), Microscopic Colitis (7 papers) and Biosimilars and Bioanalytical Methods (7 papers). Giuseppe Privitera collaborates with scholars based in Italy, United States and Israel. Giuseppe Privitera's co-authors include Alessandro Armuzzi, Daniela Pugliese, Nitish Rana, Theresa T. Pizarro, Antonio Gasbarrini, Franco Scaldaferri, Luisa Guidi, Andrei I. Ivanov, Sara Onali and Loris Riccardo Lopetuso and has published in prestigious journals such as Cell, Gastroenterology and Trends in Cell Biology.

In The Last Decade

Giuseppe Privitera

30 papers receiving 649 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis

2022 144 citations Nitish Rana, Giuseppe Privitera et al. Cell profile →

Peers

Countries citing papers authored by Giuseppe Privitera

Since Specialization

Citations

This map shows the geographic impact of Giuseppe Privitera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giuseppe Privitera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giuseppe Privitera more than expected).

Fields of papers citing papers by Giuseppe Privitera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giuseppe Privitera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giuseppe Privitera. The network helps show where Giuseppe Privitera may publish in the future.

Co-authorship network of co-authors of Giuseppe Privitera

This figure shows the co-authorship network connecting the top 25 collaborators of Giuseppe Privitera. A scholar is included among the top collaborators of Giuseppe Privitera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giuseppe Privitera. Giuseppe Privitera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug Development in Inflammatory Bowel Diseases: What Is Next? 2025 ·Pharmaceuticals ·(unknown), Arianna Dal Buono, Roberto Gabbiadini, (unknown), Giuseppe Privitera, (unknown), Laura Loy, Cristina Bezzio, Alessandro Armuzzi	4
2	Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study 2025 ·Digestive and Liver Disease ·Giuseppe Privitera, (unknown), (unknown), Elisa Schiavoni, Daniele Napolitano, (unknown), Angela Barini, Barbara Tolusso, Lucrezia Laterza, Antonio Gasbarrini, Franco Scaldaferri, Daniela Pugliese, Alessandro Armuzzi	0
3	GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation 2025 ·Frontiers in Immunology ·(unknown), Roberto Gabbiadini, Arianna Dal Buono, (unknown), Giuseppe Privitera, (unknown), (unknown), Cristina Bezzio, Alessandro Armuzzi	3
4	Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 2024 ·Journal of Clinical Medicine ·(unknown), Giuseppe Privitera, Federica Di Vincenzo, (unknown), (unknown), Luigi Carbone, Franco Scaldaferri, Daniela Pugliese	2
5	The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric Cancer 2024 ·Cancers ·Giuseppe Privitera, Joseph Jay Williams, Carlo De Salvo	6
6	Crohn’s Disease: Radiological Answers to Clinical Questions and Review of the Literature 2024 ·Journal of Clinical Medicine ·Laura Maria Minordi, (unknown), Giuseppe Privitera, Alfredo Papa, (unknown), Lucrezia Laterza, Franco Scaldaferri, Brunella Barbaro, Luigi Carbone, Daniela Pugliese	2
7	New drugs for the treatment of IBD during conception, pregnancy, and lactation 2023 ·Digestive and Liver Disease ·Daniela Pugliese, Giuseppe Privitera, Javier P. Gisbert, María Chaparro	13
8	The gasdermin protein family: emerging roles in gastrointestinal health and disease 2023 ·Nature Reviews Gastroenterology & Hepatology ·Giuseppe Privitera, Nitish Rana, Alessandro Armuzzi, Theresa T. Pizarro	45
9	GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis breakdown → 2022 ·Cell ·Nitish Rana, Giuseppe Privitera, Hannah Kondolf, Katarzyna Bulek, Susana Lechuga, Carlo De Salvo, Daniele Corridoni, Agne Antanaviciute, Rebecca L. Maywald, (unknown), Junjie Zhao, Emina H. Huang, Xiaoxia Li, E. Ricky Chan, Alison Simmons, Giorgos Bamias, Derek W. Abbott, Jason D. Heaney, Andrei I. Ivanov, Theresa T. Pizarro	144
10	The enigmatic roles of epithelial gasdermin B: Recent discoveries and controversies 2022 ·Trends in Cell Biology ·Andrei I. Ivanov, Nitish Rana, Giuseppe Privitera, Theresa T. Pizarro	32
11	Novel Insights Into the Interactions Between the Gut Microbiome, Inflammasomes, and Gasdermins During Colorectal Cancer 2022 ·Frontiers in Cellular and Infection Microbiology ·Giuseppe Privitera, Nitish Rana, Franco Scaldaferri, Alessandro Armuzzi, Theresa T. Pizarro	21
12	Challenges in Crohn’s Disease Management after Gastrointestinal Cancer Diagnosis 2021 ·Cancers ·Claudio Fiorillo, Carlo Alberto Schena, Giuseppe Quero, Vito Laterza, Daniela Pugliese, Giuseppe Privitera, Fausto Rosa, Tommaso Schepis, Lisa Salvatore, (unknown), (unknown), Laura Maria Minordi, Luigi Natale, Giampaolo Tortora, Alessandro Armuzzi, Sergio Alfieri	8
13	Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 2021 ·Autoimmunity Reviews ·Giuseppe Privitera, Daniela Pugliese, Sara Onali, Valentina Petito, Franco Scaldaferri, Antonio Gasbarrini, Silvio Danese, Alessandro Armuzzi	49
14	Effects of infections on the pathogenesis of cancer 2021 ·The Indian Journal of Medical Research ·(unknown), (unknown), Corrado Spatola, (unknown), Giuseppe Privitera, Francesco Basile, Antonio Biondi, Marco Vacante	17
15	Sa1877 EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS 2020 ·Gastroenterology ·Giuseppe Privitera, Daniela Pugliese, Barbara Tolusso, Elisa Gremese, Alfredo Papa, Luigi Giovanni Papparella, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi	1
16	Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 2020 ·Alimentary Pharmacology & Therapeutics ·Lorenzo Bertani, Domenico Tricò, Daniela Pugliese, Giuseppe Privitera, Giuseppe Linsalata, Federico Zanzi, M.G. Mumolo, Brigida Barberio, Fabio Monzani, Santino Marchi, Luisa Guidi, Corrado Blandizzi, Alessandro Armuzzi, Francesco Costa	17
17	The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable” 2020 ·Digestive and Liver Disease ·Daniela Pugliese, Claudio Papi, Giuseppe Privitera, Annalisa Aratari, Stefano Festa, Alessandro Armuzzi	2
18	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 2020 ·PubMed ·Daniela Pugliese, Giuseppe Privitera, Fabrizio Pizzolante, Antonio Gasbarrini, Luisa Guidi, Alessandro Armuzzi	3
19	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 2020 ·Expert Opinion on Biological Therapy ·Daniela Pugliese, Luisa Guidi, Giuseppe Privitera, Lorenzo Bertani, Barbara Tolusso, Luigi Giovanni Papparella, S. Maltinti, Clara Di Mario, Sara Onali, Linda Ceccarelli, Gian Lodovico Rapaccini, Franco Scaldaferri, Elisa Gremese, Antonio Gasbarrini, Francesco Costa, Alessandro Armuzzi	8
20	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 2019 ·United European Gastroenterology Journal ·Luisa Guidi, Daniela Pugliese, (unknown), Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini, Alessandro Armuzzi	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact